Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2018, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Optic Neuropathy - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy - Overview
Optic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy - Companies Involved in Therapeutics Development
Amgen Inc
Ironwood Pharmaceuticals Inc
Quark Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Optic Neuropathy - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002Fab3H4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IWP-953 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on Stroke of the Eye'
Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
Sep 18, 2012: Neurotech Pharmaceuticals Provides Update On NT-501
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Optic Neuropathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Optic Neuropathy - Pipeline by Amgen Inc, H1 2018
Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2018
Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2018
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Optic Neuropathy - Dormant Projects, H1 2018
Optic Neuropathy - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Optic Neuropathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Artificial Tears Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 91
Artificial tears are lubricant eye drops used to treat The dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations.
The global Artificial Tears market was valued at US$ 2921.6 million in 2023 and is anticipated to reach US$ 5240.1 million by 2030, witnessing a CAGR of 8.6% during The forecast period 2024-2030.
The industry's leading producers are Aller......
Global Contact Lens Solution Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 96
Contact lens solution is a kind of solution that is used to contact lens with The function of cleaning, disinfection, rinsing or preservation, it can also alleviate The eyeball discomfort which caused by wear The contact lens. Contact lens solution can direct contact eyeball, so it must be accord with industrial standard.
The global Contact Lens Solution market was valued at US$ 4087.6 million in 2023 and is anticipated to reach US$ 5323.5 million by 2030, witnessing a CAGR of 3.8% ......
Global Latanoprost Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 82
Latanoprost drops is a clear colorless liquid and a medication used to treat increased pressure inside The eye. Onset of effects is usually within four hours, and they last for up to a day.
Latanoprost is used to treat high pressure inside The eye due to glaucoma (open angle type) or other eye diseases (e.g., ocular hypertension). It is similar to a natural chemical in The body (prostaglandin) and works by regulating The flow of fluid within The eye which results in lower pressure. Lowerin......
Global Contact Lens Solution Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 99
Market Overview of Global Contact Lens Solution market:
According to our latest research, the global Contact Lens Solution market looks promising in the next 5 years. As of 2022, the global Contact Lens Solution market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Contact ......
Global Dry Eye Syndrome Drugs Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 82
The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive......
Global Eye Drops & Lubricants Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 112
According to our LPI (LP Information) latest study, the global Eye Drops & Lubricants market size was valued at US$ 8841.8 million in 2023. With growing demand in downstream market, the Eye Drops & Lubricants is forecast to a readjusted size of US$ 9780.8 million by 2030 with a CAGR of 1.5% during review period.
The research report highlights the growth potential of the global Eye Drops & Lubricants market. Eye Drops & Lubricants are expected to show stable growth in the future market. H......
Global Conjunctivitis Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 98
According to our LPI (LP Information) latest study, the global Conjunctivitis market size was valued at US$ 3482.7 million in 2023. With growing demand in downstream market, the Conjunctivitis is forecast to a readjusted size of US$ 3908 million by 2030 with a CAGR of 1.7% during review period.
The research report highlights the growth potential of the global Conjunctivitis market. Conjunctivitis are expected to show stable growth in the future market. However, product differentiation, r......
Global Contact Lens Solution Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 118
According to our LPI (LP Information) latest study, the global Contact Lens Solution market size was valued at US$ 3998.7 million in 2023. With growing demand in downstream market, the Contact Lens Solution is forecast to a readjusted size of US$ 5241.5 million by 2030 with a CAGR of 3.9% during review period.
The research report highlights the growth potential of the global Contact Lens Solution market. Contact Lens Solution are expected to show stable growth in the future market. Howev......
Global Latanoprost Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 90
According to our LPI (LP Information) latest study, the global Latanoprost market size was valued at US$ 1344.2 million in 2023. With growing demand in downstream market, the Latanoprost is forecast to a readjusted size of US$ 1574.2 million by 2030 with a CAGR of 2.3% during review period.
The research report highlights the growth potential of the global Latanoprost market. Latanoprost are expected to show stable growth in the future market. However, product differentiation, reducing co......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
